01OverviewDefinition, clinical context and the essential points that orientate the chapter.
Barrett metaplasia replaces distal squamous lining with columnar epithelium visible above the gastro-oesophageal junction. It is a marker of increased adenocarcinoma risk, but absolute progression varies with segment length, age, sex, smoking, family history and histology. The surveillance decision should account for health, life expectancy, procedural risk and the person’s preferences rather than operate as an automatic lifelong test.
A high-quality examination records landmarks and maximum and circumferential extent, clears mucus, inspects slowly and targets visible lesions. The Seattle protocol adds four-quadrant biopsies every 2 cm. Active reflux inflammation can mimic dysplasia; indefinite findings prompt acid optimisation and six-month surveillance. Low-grade dysplasia needs confirmation from biopsies at two separate endoscopies and review by two GI pathologists before ablation.
Endoscopic resection supplies definitive depth, margin and lymphovascular information for visible lesions and suspected stage 1 cancer. T1a adenocarcinoma is usually treated by resection plus ablation of residual Barrett mucosa. T1b disease has higher nodal risk; fit patients with incomplete resection, lymphovascular invasion or deep submucosal invasion should be offered oesophagectomy. Follow-up continues after eradication because metaplasia and neoplasia can recur.
Key points
- Barrett oesophagus is visible columnar-lined distal oesophagus of at least 1 cm confirmed histologically, arising in the setting of reflux and carrying adenocarcinoma risk.
- Use high-resolution white-light surveillance with Seattle protocol biopsies plus targeted sampling of every visible abnormality.
- NICE offers surveillance every two to three years for segments at least 3 cm and every three to five years for short segments under 3 cm with intestinal metaplasia.
- Do not surveil a short segment under 3 cm without intestinal metaplasia after the diagnosis has been confirmed at two endoscopies.
- Offer resection of visible high-grade lesions followed by ablation of residual Barrett mucosa; confirmed low-grade dysplasia at two endoscopies is treated with radiofrequency ablation.
- Do not start aspirin or antireflux surgery solely to prevent Barrett progression; manage reflux for its own indications.
02AetiologyUnderlying causes, associations and risk factors, with why each one matters.
Chronic reflux association
Repeated gastro-oesophageal reflux promotes replacement of injured squamous lining by a columnar phenotype better adapted to acid exposure.
Host risk factors
Male sex, increasing age, central adiposity, smoking and family history influence the likelihood of Barrett metaplasia and neoplastic progression.
03PathophysiologyThe causal sequence from the underlying abnormality to symptoms and harm.
- 1Metaplastic adaptation
Columnar epithelium replaces the distal squamous mucosa as an acquired response to chronic acid and bile exposure in a reflux-injured oesophagus.
- 2Clonal dysplasia
Accumulating genetic and epigenetic alterations create low-grade then high-grade architectural and cytological abnormality within the metaplastic field before invasive adenocarcinoma emerges.
- 3Invasive transition
Neoplastic glands cross the basement membrane and may enter submucosal lymphatics, sharply increasing nodal metastatic risk at T1b stage.
04Clinical features and red flagsSymptoms, examination findings, patterns of presentation and time-critical warnings.
Visible segment length and confirmed intestinal metaplasia determine whether and how often surveillance is offered.
Inflammation prevents reliable grading, so acid suppression is optimised and endoscopy repeated at six months.
Biopsies at two separate endoscopies and agreement of two GI pathologists support radiofrequency ablation.
A focal abnormality needs endoscopic resection for staging before residual-field ablation.
Deep submucosal invasion, lymphovascular invasion or incomplete resection increases lymph-node risk and shifts fit patients toward oesophagectomy.
05InvestigationsWhat to request, why it matters and how to interpret it.
Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.
- 01
High-resolution white-light endoscopyFirst step - Why
- Inspect the whole segment and identify visible neoplasia.
- Interpretation and limitations
- Record junction landmarks and Barrett extent, target every lesion and assess whether inflammation impairs histological interpretation.
- 02
Seattle protocol biopsies - Why
- Sample apparently flat mucosa systematically during surveillance.
- Interpretation and limitations
- Take four-quadrant biopsies every 2 cm plus targeted biopsies; incomplete sampling reduces sensitivity for focal dysplasia.
- 03
Expert histopathology review - Why
- Confirm dysplasia grade before ablation or cancer surgery.
- Interpretation and limitations
- Inflammation and regenerative atypia create overdiagnosis; two GI pathologists should confirm low-grade dysplasia used for ablation decisions.
- 04
Endoscopic resection - Why
- Stage a visible lesion or suspected T1 adenocarcinoma.
- Interpretation and limitations
- The specimen establishes invasion depth, differentiation, margins and lymphovascular invasion more accurately than superficial forceps biopsy.
- 05
EUS for selected T1b disease - Why
- Assess nodes when submucosal invasion is suspected or proven.
- Interpretation and limitations
- NICE does not recommend EUS before resection for suspected T1a disease; histology from resection decides whether nodal staging is needed.
06Differential diagnosisRealistic alternatives and the features that help distinguish them.
Inflamed gastric cardia
An irregular junction or cardia intestinal metaplasia can be mislabelled Barrett unless landmarks and at least 1 cm of visible oesophageal columnar mucosa are documented.
Reflux atypia
Active inflammation produces reactive nuclear change that can be mistaken for dysplasia and requires expert review after acid control.
Early squamous neoplasia
A separate squamous lesion has different histology, risk factors and ablation strategy despite sharing the oesophageal location.
07ManagementImmediate care, first-line treatment, alternatives and escalation.
01SurveillanceApply interval to histology and lengthFirst stepA fit person has a 4 cm non-dysplastic Barrett segment with intestinal metaplasia.+
- 1Discuss the benefit, procedural risk and limitations of surveillance.
- 2Offer high-resolution endoscopy with Seattle biopsies every two to three years, tailored within that range to individual cancer risk.
- 3EscalationEscalate any visible lesion to targeted resection rather than relying on random biopsy alone.
- 4Verify pathology, segment length and the next due date in a tracked recall system.
02Low-grade dysplasiaConfirm before ablationLow-grade dysplasia is reported from one surveillance examination.+
- 1Arrange expert pathology review and repeat endoscopic assessment after optimising mucosal conditions.
- 2If low-grade dysplasia is present on biopsies from two separate endoscopies and two GI pathologists confirm it, offer radiofrequency ablation.
- 3Discuss strictures, bleeding, incomplete eradication and follow-up.
- 4Verify eradication and recurrence surveillance through protocolled endoscopy.
03Visible high-grade lesionResect then treat the fieldA focal nodule contains high-grade dysplasia.+
- 1Perform expert endoscopic resection to stage the lesion and inspect margins.
- 2Offer ablation of residual Barrett mucosa after visible disease has been removed.
- 3EscalationEscalate adverse histological features or T1b invasion to the cancer MDT for surgery or non-surgical alternatives.
- 4Confirm follow-up ownership because treatment does not abolish recurrence risk.
Key medicines and prescribing safety1 treatment · regimens, roles and cautions+
Omeprazole for coexisting reflux
Treat the separate reflux indication rather than Barrett metaplasia itself: for uncomplicated symptomatic GORD use omeprazole 20 mg orally once daily before food for four weeks, extending to eight weeks if needed. For severe reflux oesophagitis use 40 mg once daily for eight weeks and continue long-term full-dose 40 mg once daily after healing; symptom-led step-down applies to uncomplicated disease.Swallow the gastro-resistant tablet whole with water and do not chew or crush it. Nelfinavir is contraindicated and concomitant clopidogrel is discouraged; hepatic impairment may require a lower dose. Review long-term safety and interactions, and do not imply that a PPI removes the need for indicated Barrett surveillance or dysplasia treatment.
08ComplicationsImportant consequences, why they occur and why they matter clinically.
Oesophageal adenocarcinoma
Progressive dysplasia can invade the wall and metastasise, with risk increasing after high-grade change and submucosal invasion.
Post-ablation stricture
Circumferential mucosal injury can scar and narrow the lumen, causing dysphagia that may need careful dilation.
Recurrent metaplasia
Barrett tissue or dysplasia can recur after apparent eradication, particularly near the junction, requiring continued endoscopic follow-up.
09Monitoring and follow-upTreatment response, safety checks and longer-term review.
- Maintain an auditable recall system containing segment length, intestinal metaplasia, dysplasia grade and last examination quality.
- Review all dysplasia through expert GI pathology before treatment.
- After ablation or resection, inspect for buried, recurrent or junctional metaplasia and treat strictures promptly.
- Continue reflux and nutritional assessment after endoscopic therapy or oesophagectomy.
- Trigger diagnostic assessment immediately for new dysphagia, bleeding or weight loss between surveillance visits.
10Special situationsVariants, exceptions and circumstances that change the usual approach.
Length changes interval
NICE separates segments at 3 cm because longer metaplastic fields carry more risk and require closer surveillance.
Visible lesions need specimens
Endoscopic resection provides invasion and margin data that forceps biopsies cannot reliably supply.
Surveillance has a stopping question
Severe comorbidity may remove any realistic benefit if the person could not undergo treatment for detected neoplasia.
Eradication needs follow-up
A visually normal neosquamous surface does not guarantee permanent eradication or eliminate junctional recurrence.
11Common pitfallsFrequent interpretation and management errors.
- 01
Scheduling every Barrett patient at the same interval regardless of length and metaplasia.
- 02
Ablating a single unconfirmed low-grade dysplasia report.
- 03
Taking random biopsies through a visible nodule instead of staging it by expert resection.
- 04
Reassuring new dysphagia because surveillance endoscopy is due next year.